Disappointingly, treatment with a humanized monoclonal neutralizing antibody against TGF-β1 (LY2382770) for patients with diabetic nephropathy shows no efficacy on the improvements of renal dysfunction including serum creatinine, estimated GFR (eGFR), and proteinuria 109. Here, TGFB1 is linked to diabetic kidney disease.